HopeStage
Back to all studies
RecruitingNCT03420339

Stimulant medicines and disruptive behavior in young people

About this titleRead the official source — NCT03420339
Medication studyAges 48 months–12 yearsUnited StatesADHD
The study in practice

Understand this study

Who could participate?

Listed age limits: 48 months to 12 years.

Listed locations
Iowa CitySee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 1, 2018
Recruitment status
Recruiting
Enrollment listed in the registry
10
Sponsor
Matthew J O'Brien, PhD, BCBA-D
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 48 Months to 12 Years
Official registry ID
NCT03420339
Official title
Show the full official title

The Effects of Stimulant Medication on Disruptive Behavior, Choice, and Preference in Children and Adolescents Exhibiting Disruptive Behavior

Recruitment & locations

Currently recruiting

Iowa City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Matthew J O'Brien, PhD, BCBA-D.

Does this study involve medication?

Yes. The study involves medication, including Stimulant.

Who can participate?

Listed age limits: 48 months to 12 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies